Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanozyme-E
- Development stage
- Preclinical
- Lead developer
- Cenyx Biotech
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
Nanozyme-E is an early-stage therapeutic candidate being developed by Cenyx Biotech, a South Korean biotechnology company focused on the development of "nanozymes"—nanomaterials that exhibit intrinsic enzyme-like activities. Nanozymes are typically designed to mimic the function of antioxidant enzymes such as superoxide dismutase (SOD), catalase, or peroxidase to mitigate oxidative stress and inflammation. While Cenyx Biotech's lead programs target acute neurological conditions, the specific chemical composition, biological target, and therapeutic indication for Nanozyme-E are currently classified as confidential by the company.
Beyond the preview
Go deeper on Nanozyme-E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanozyme-E.